Merck Serono SA

The Merck Serono Biotech Center (MSBC) in Corsier-sur-Vevey, Switzerland, is one of seven sites operated by Biotech & Manufacturing Process Development. This highly specialized group focuses on the production of Merck Serono Biotech products for clinical trials and commercial phases, as well as the development of high-performance processes. This site has particular expertise in mammalian cell technologies at both small and medium-scale, utilizing many different technological platforms.
The MSBC is one of the largest and most technologically advanced biotechnology facilities in the world. Opened in 1999, the site currently produces the active ingredient for Merck Serono's multiple sclerosis treatment, Rebif® (interferon beta-1a). An expansion project to increase the site's capacity was recently completed to enable the production of additional drugs, including the targeted cancer treatment Erbitux® (cetuximab).